Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Renal Cell 19Kidney Neoplasms 3Urinary Bladder Neoplasms 1Urethral Neoplasms 1Prostatic Neoplasms 1Melanoma 1Margins of Excision 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Carcinoma 1Adenocarcinoma 1

Interventions

pembrolizumab 6Radiosurgery 5Docetaxel 5enzalutamide 4darolutamide 3Radiotherapy 3Everolimus 3Androgen Antagonists 3relugolix 2luprolide acetate gel depot 2Surveys and Questionnaires 2Standard of Care 2Radiotherapy, Image-Guided 2Radiofrequency Ablation 2Panobinostat 2Leuprolide 2Abiraterone Acetate 2trastuzumab deruxtecan 1talazoparib 1spartalizumab 1siremadlin 1sipuleucel-T 1sargramostim 1resiquimod 1polysaccharide-K 1poly ICLC 1palbociclib 1olaparib 1liposomal doxorubicin 1ixabepilone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenocarcinoma × Interferon alpha-2 × Genitourinary × Clear all
NCT00719264 2017-03-20

Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney Cancer

Novartis

Phase 2 Completed
365 enrolled 14 charts
Genitourinary

Margins of Excision, Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡